Pipeline

Our focus on new product development for musculoskeletal pain and pain adjacencies is motivated by the significant need for innovation in this space.

Developing better solutions to pain relief

We refuse to settle for therapies that are just “good enough.” Patients deserve better solutions that will not only help them get back to normal but remove the daily interferences caused by pain. Precise, targeted treatments have the potential to transform how pain is managed, and Pacira is at the forefront of this shift.

Our growing pipeline builds on our legacy of best-in-class, locally administered, long-acting, opioid-sparing therapies. From expanding proven solutions to investing in breakthroughs like gene therapy, we are committed to delivering medicine where it matters most.

Product
Target
Preclinical
Phase 1
Phase 2
Phase 3
Rights
ZILRETTA®
(triamcinolone acetonide)
Shoulder OA
Rights: Pacira
Pacira
ioveraº®
Spasticity
Rights: Pacira
Pacira
EXPAREL®
(bupivacaine liposome)
Acute Post-Surgical Pain
Pediatric 0 to < 6
Pacira
Pacira
PCRX-201
Knee OA
Rights: Pacira
Pacira
PCRX-2002
Post-Surgical Pain
Rights: AmacaThera
AmacaThera
A woman with long gray hair sits on an open-air bus, gazing into the distance.
A woman with long gray hair sits on an open-air bus, gazing into the distance.

Better
is Possible.

Let’s innovate together

Collaboration drives progress, and we’re proud to work with organizations that share our vision for advancing pain management.